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SIGNIFICANCE
Melanoma incidence and mortality like all cancers increase 
with age. However, the association between age and both 
melanoma risk and prognostic factors is complex. Naevi 
undergo a significant senescence with age and yet mela-
noma incidence increases with age. 
Sentinel node biopsy is an important prognostic factor in 
melanoma, yet sentinel node positivity is higher in younger 
age groups despite their better prognosis. Telomere biology 
and delayed ageing are tightly linked to melanoma suscepti-
bility. BRAF positivity is also associated with age and naevus 
counts. Age should be taken into account when interpreting 
sentinel node biopsy results but also when planning immun-
otherapy and targeted therapy treatments. 
As for all types of cancer, the incidence of melanoma 
increases with age. However, naevus counts (the prin-
cipal risk factor for melanoma) decrease with age; 
hence the relationship between ageing and melanoma 
is complex. Subjects who maintain a high naevus count 
after the age of 50 years are more likely to be affected 
by melanoma, as their lesions do not senesce. Longer 
telomere length, which is strongly related to age, is 
linked to high naevus counts/melanoma risk; thus me-
lanoma biology is influenced by factors that slow down 
ageing. Age is also an important prognostic factor in 
melanoma. Increasing age leads to worse survival in 
stages I, II and III. Sentinel lymph node (SLN) status, 
which is a strong predictor of melanoma survival, is 
also affected by age, as SLN positivity decreases with 
age. However, the prognostic value of SLN on survi-
val increases with age, so, again, these relationships 
are complex. In patients with stage IV melanoma, 
age impacts on survival because it affects responses 
to treatment. This review examines the effects of age 
on melanoma risk, prognostic factors and responses to 
treatment. 
Key words: age; ageing; sentinel lymph node; prognosis; 
therapy.
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The articles forming the basis of this review were collected by searching MEDLINE, Scopus and the 
Cochrane Library from 1 January 1980 to 1 June 2017, 
using the following keywords: “naevi”, “naevus count”, 
“melanoma”, “ageing”, “age”, “senescence”, “follow-
up”, “survival”, “prognosis” and “treatment”. The most 
significant publications were included in the study and 
discussed. Article titles and abstracts were used for initial 
screening, followed by a review of the full text. Only 
original manuscripts in English language were included. 
Searches were supplemented by scanning the biblio-
graphies of included articles for further relevant articles.
AGEING
Ageing represents the accumulation of changes in human 
beings over time, encompassing physical, psychologi-
cal, and social changes. Ageing is among the greatest 
known risk factors for most human diseases (1) and is one 
of the most important risk factors for cancer. After many 
replications our cells have an increased chance of somatic 
mutations, which may lead to uncontrolled growth. Due 
to an inherent end-replication process, chromosomes are 
exposed to a potential loss of genetic material and telo-
meres act as a buffer against loss of chromatin. Telomeres 
are repeated TTAGGG sequences at the end of linear 
chromosomes, which guard against this loss of genetic 
material during cellular replication. Repeated cell cycles 
eventually lead to a critically shortened telomere length, 
which signals cellular senescence to trigger apoptosis. 
This arrested proliferation is thought to protect against 
malignant transformation, and a failure in this protec-
tive mechanism can result in genomic instability and 
carcinogenesis. Telomere length therefore shortens with 
age (2). The rate of biological ageing in humans varies 
greatly and this can be estimated, in part, by assessing 
telomere shrinkage with age. Longer telomeres have 
been linked with higher naevus counts and melanoma 
risk, and genes that influence telomere length have been 
linked with melanoma risk via genome-wide association 
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studies (GWAS). In the clinical setting, it is apparent 
that melanoma patients often appear younger than their 
chronological age and it is likely that identifying the gap 
between chronological age and biological age will shed 
some light on melanoma risk, but may also explain dif-
ferences regarding responses to treatment. 
Ageing, naevi and melanoma risk
Number of naevi is a reliable phenotypic marker of 
ageing. Naevi typically involute after the fourth decade 
of life in Caucasian populations and are rare in elderly 
people. This process is likely to be, in part, genetically 
driven. However, the rate at which naevi disappear with 
age varies greatly, with some individuals still having 
large numbers of naevi in late middle-age. This sug-
gests that reduced senescence in the melanocytic system 
may be a good predictor of melanoma risk. Oncogene 
(BRAF and RAS) and tumour suppressor (p16, p14arf, 
p53, PTEN, Rb) driven cell senescence is important in 
melanocytes. PTEN depletion and the pI3K pathway are 
also thought to be important in inhibiting BRAF-induced 
senescence in naevi (3). Longer telomere length is an-
other important genetic marker of reduced senescence, 
as both naevi count and melanoma are associated with 
longer telomeres (4). This suggests that individuals with 
a large of number of naevi may have reduced senescence 
and increased longevity (5–7). In 2011, melanoma case 
control studies replicated these findings in melanoma 
(8, 9). More recently, germline amplifications of the 
TERT promoter have been reported in rare melanoma 
families and this has been replicated at the somatic level 
in many melanoma tumours (10, 11). POT1, another 
gene controlling telomere length has also been linked 
with melanoma (12). Several single-nucleotide poly-
morphisms (SNPs) affect telomere length, and many of 
these SNPs have been associated with melanoma risk, 
supporting the role of ageing in melanoma. Longevity 
may therefore be a trade-off for increased melanoma 
risk, as many patients with melanoma survive their 
disease, highlighting the fine balance between ageing 
and cancer (13). 
Age and stage I and II melanoma
It is well established that the mortality rate from mela-
noma increases with age (14). Although this might be 
attributed to thicker and ulcerated melanomas in older 
patients, age has been noted to be an independent adverse 
prognostic indicator of overall survival (OS) (15, 16). 
Number of naevi is considered a good marker of ageing. 
While naevus count is a robust risk factor for melanoma, 
high naevus count, in turn, is associated with improved 
survival (17). Melanoma cases with a high naevus count 
showed a reduction of 57% in melanoma-specific morta-
lity (hazard ratio (HR) = 0.43, 95% CI 0.21–0.89). The 
improved survival in melanoma cases with high naevus 
counts suggests that the genetic determinants of naevi 
number may be associated with biological differences in 
melanoma tumours. Breslow thickness increases with age 
as well as ulceration rate, possibly due to late diagnosis 
in older patients. However, it is possible that, with age, 
a less efficient immune system leads to more aggressive 
tumours. 
Age and sentinel lymph node status
Since the introduction of sentinel lymph node (SLN) 
biopsy in melanoma by Morton et al. (18) in the early 
1990s, the early identification of regional node metasta-
ses has been considered the most important prognostic 
factor for patients with melanoma. Originally, SLN was 
not offered to patients over 75 years of age, as it was 
considered that the morbidity was too great in these age 
groups, especially in the light of a lack of therapeutic 
benefit. With increasing life expectancy and with ex-
perience showing the ability of SLN biopsy to stratify 
patients in different risk categories (thus permitting the 
enrolment in trials on adjuvant treatments), many centres 
are now offering SLN biopsy in elderly patients. SLN 
has been reported to be a safe procedure in older age (19) 
and morbidity is quite limited (20). 
SLN status has been described as a prognostic feature, 
but its role in predicting survival changes significantly 
according to the age of the patient. Many studies have 
previously reported the paradox of decreased SLN 
positivity with age, whilst there is increased mortality 
in elderly subjects for the same Breslow thickness (21, 
22). Despite this, no clear biologic explanation has been 
given for this observation so far. Although age is known 
to be an important predictor of outcome in melanoma, 
it has not been included in the current staging system 
for melanoma, which was most recently revised by the 
American Joint Committee on Cancer (AJCC). The 
reason why SLN may be more likely to be positive in 
younger patients may be because melanocytes are less 
senescent and more likely to travel to the sentinel node. 
However, whilst settled in the sentinel node, it is likely 
that a younger immune system will be more effective 
at containing the tumour there (23–25). Conversely, in 
older patients, melanocytes may be less likely to reach 
the sentinel node, but, when they do, they may not be 
successfully controlled by the immune system locally. 
How to plan a follow-up adapted to age
The main aim of follow-ups in patients with melanoma is 
the earliest detection of recurrent disease, the diagnosis 
of secondary skin cancers and their prevention, through 
the adoption of healthy lifestyles. Currently there is 
no scientific evidence that follow-ups improve clinical 
outcomes for patients with melanoma. In patients with 
early-stage tumours, the optimal duration of follow-up 
has not been standardized. Relapse of disease occurs 
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most commonly in the first 5 years after diagnosis, mostly 
within the first 2 years. Most of these are detected by the 
patient and not by their physician. The risk of developing 
a second melanoma in a subject is approximately 4–8%, 
so follow-ups at least offer some screening for these 
subsequent tumours.
Individual follow-ups are acceptable according to the 
presence of several risk factors, such as age, family his-
tory of melanoma and other cancers, the presence of mul-
tiple dysplastic naevi and skin type. It is also important 
to educate patients about skin self-examination and the 
main lymph node drainage areas. This is particularly 
important, since early surgical treatment of individual 
metastases, especially if they are found in lymph nodes, 
lung, spleen or subcutaneous tissue, has a very favourable 
effect on both quality of life and life expectancy. 
Among studies that have evaluated the best timing of 
follow-up, the study of the Australian group compared 
2 different follow-up schedules: the first included a 
skin check every 6 months for 5 years and then a yearly 
check for a further 5 years in patients with stage I; for 
patients with stage II, a check every 3 months to 5 years 
and then yearly for an additional 5 years. The second 
proposed schedule was an annual check for 10 years 
in patients with stage I, a check every 6 months for 2 
years and then annually for a further 8 years in patients 
with stage IIA, and every 4 months for 2 years, every 6 
months the third year and then annually for a further 7 
years in patients with stage IIB–IIC. The more intensive 
follow-up made it possible to detect 44 recurrences and 
10 new primary melanomas 2 months earlier compared 
with the less intensive follow-up (26). More recently, a 
paper by Tas & Erturk (27) showed that nearly one-third 
of 332 patients enrolled, all of them initially diagnosed 
with non-metastatic melanoma, developed recurrence 
during the disease course and/or follow-up. They were 
divided into 3 groups according to the pattern of disease 
spread: (i) locoregional relapse alone (including regional 
lymph node metastases, distant skin, subcutaneous, and 
satellite/in-transit metastases); (ii) mixed relapse (loco-
regional relapse and distant metastases); and (iii) distant 
metastases alone. The median time of recurrences was 
16.5 months: locoregional relapse alone was most fre-
quently associated with earlier stage melanomas, whilst 
distant metastases alone were mostly observed with 
stage III and axial melanoma, or in patients with higher 
serum lactate dehydrogenase concentration. Nearly two-
thirds of the relapse occurred within the first 2 years 
from diagnosis. Even though no association was found 
between the time of recurrence and the site of relapse 
sites, a significant survival advantage was observed in 
locoregional relapse alone compared with other relapse 
patterns (p < 0.0001). This is why follow-ups can make 
a difference when patients can be detected at the time of 
loco-regional relapse.
Age and stage IV melanoma
Impact of age on immunotherapies. Immune checkpoint 
inhibitors (antiCTLA4, antiPD1) have radically chan-
ged the prognosis of melanoma patients, leading to an 
increasing number of patients with long-term survival 
for stage 3 and 4. These drugs remove the inhibitory 
immunomodulatory signals from the tumour, enhancing 
T-lymphocyte activity against melanoma cells. There are 
age-associated impairments of the immune system, called 
the “immunosenescence” phenomenon (28, 29), which 
could affect the efficacy and/or toxicity of the immune 
checkpoint blockade. In fact, with ageing, the expression 
patterns of T-cell co-stimulatory or co-inhibitory proteins 
change considerably: the expression of inhibitory recep-
tors, such as PD-1 or LAG-3, is enhanced, associated 
with a decrease in co-stimulatory molecules. Therefore, 
data on the impact of age on the efficacy and safety of 
these drugs are challenging. The first therapeutic agent 
approved by the FDA for metastatic melanoma was 
ipilimumab, a fully humanized monoclonal antibody 
directed against CTLA-4. In the phase 3 pivotal trial, 676 
patients were randomized 3.1:1 to receive ipilimumab 
3 mg/kg, ipilimumab plus gp100 peptide vaccine, or 
gp100 vaccine alone. Among these 676 patients on this 
trial, 196 (29%) were aged over 65 years. Analyses of 
OS in these subgroups showed, however, that the effects 
of ipilimumab were independent of age. For the whole 
cohort, the median OS was 10.0 months among patients 
receiving ipilimumab plus gp100, compared with 6.4 
months among patients receiving gp100 alone (HR for 
death 0.68; p < 0.001). The median OS with ipilimumab 
alone was 10.1 months (HR for death in the comparison 
with gp100 alone 0.66; p = 0.003). In the elderly popula-
tion, a 31% reduction in the risk of death was noted with 
ipilimumab plus gp100, compared with gp100 alone (HR 
0.69 (0.47–1.01)), and a 39% reduction in risk of death 
was seen with ipilimumab alone compared with gp100 
alone (HR 0.61 (0.38–0.99)).
The use of ipilimumab in older patients in a clinical 
setting is described in a retrospective trial conducted in 
Italy (30). This study assessed the efficacy and safety of 
ipilimumab at its approved dose of 3 mg/kg in elderly 
patients within an expanded access programme. Data 
were collected from 193 patients over 70 years of age 
who treated with ipilimumab 3 mg/kg. Twenty-seven 
patients were aged over 80 years. There was no dif-
ference in median OS between ≥ 70 years (8.9 months 
(95% CI 7.2–10.6)) and < 70 years (7.0 months (95% CI 
6.1–7.9)); p = 0.17. The immune-related disease control 
rate (irDCR) was 38%, with 2% of irCR (complete re-
sponse), 13% with irPR (partial response) and 23% with 
irSD (stable disease). The median duration of irDC was 
11.5 months (95% CI 9.3–13.7). 
Major data on the use of CTLA4 or anti PD1 in an 
elderly population were available from a review by 
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Friedman and colleagues, reviewing all patients aged 80 
years and older at the Memorial Sloan Kettering Cancer 
Center treated with immune checkpoint blockade (anti-
CTLA4 or anti-PD1) for stage 3 or 4 unresected mela-
noma be tween January 2008 and December 2015. All 
patients had at least one infusion visit and one follow-up 
visit, and 12 patients in the ipilimumab group received 
subsequent anti-PD-1 therapy and were included in 
the toxicity analyses for both agents. Patients aged 80 
years and older treated with ipilimumab had durable 
survival at a rate similar to that of the overall popula-
tion. An immunrelated adverse events (irAE) occurred 
in 88% of the 74 patients in the ipilimumab group, and 
30% experienced a grade 3 or 4 irAE. The most com-
mon high-grade irAEs in this group were diarrhoea, 
transaminitis and rashes. Of the 25 patients receiving 
pembrolizumab or nivolumab, 84% experienced an 
irAE, and 16% experienced a grade 3 event. The most 
common adverse events in this group were pruritus, rash, 
fatigue, and musculoskeletal complaints, and one case 
each of grade 3 of elevated lipase, diarrhoea, anaemia, 
and nausea occurred. Of the 8 patients who received 
combination ipilimumab/nivolumab, 88% experienced 
any irAE and 63% experienced a high-grade 3 or 4 irAE. 
The most common high-grade irAEs in this group were 
elevated lipase, diarrhoea and transaminitis, occurring in 
38%, 25% and 25% of patients, respectively. No deaths 
occurred in any of the groups (31).
Data from the Italian expanded access programme for 
ipilimumab reported that patients over 70 years of age 
presented irAE with a similar frequency to that of the 
overall population (26). Also, the anti-PD-1, nivolumab 
seems to have the same toxicity profile in an elderly 
population as in younger population.
A more recent retrospective analysis compared irAEs 
in melanoma patients < 65 years of age with those in 
patients > 65 years of age treated with nivolumab (26). 
This study showed no statistically significant differences 
in incidence of irAEs, and the irAE profile was similar 
in the 2 groups. Thus, despite speculation about the spe-
cificities of older adult immunity, the current safety data 
appears to be similar to the population at large.
Impact of age on targeted therapy
There is an inverse relationship between BRAF mutation 
prevalence and age (32). Menzies and colleagues conduc-
ted investigated BRAF mutation status by age-decade: 
BRAF-mutant metastatic melanoma was associated with 
significantly younger age at diagnosis of first distant 
metastasis compared with BRAF wild-type melanoma 
(mean, 53.9 vs. 62.7 years) (32). All patients younger 
than 30 years had BRAF-mutant metastatic melanoma, 
compared with only 25% of patients older than 70 years. 
An association between age and BRAF-mutant genotype 
was also observed, with the frequency of non-V600E 
genotypes (including V600K) increasing with older age: 
less than 20% of BRAF-mutant patients under 50 years 
of age were non-V600E, compared with more than 40% 
of patients over 70 years of age (32).
The identification of an age-specific prevalence does 
not obviate the need for BRAF mutation testing in patients 
with metastatic melanoma, but this information may as-
sist clinical judgment, planning and pre-test counselling. 
In terms of side-effects of targeted therapy, elderly 
patients are well represented in targeted therapy clinical 
trials for metastatic melanoma (33–37). However, elderly 
patients may be more likely to have severe adverse 
events. In the safety study of vemurafenib, more than 
3,000 patients received at least one dose of vemurafenib 
and 257 patients were over 75 years of age (38). Severe 
adverse events (grades 3 and 4) and adverse events 
leading to discontinuation were reported more frequently 
in patients aged 75 years and older than in those younger 
than 75 years (38). The adverse events were predomi-
nantly cutaneous squamous cell carcinomas, keratoa-
canthomas and QTc prolongation. Skin side-effects are 
a possible consequence of a greater susceptibility to 
non-melanoma skin cancers due to long-term sun damage 
in elderly subjects and coexistent cardiac comorbidity 
in case of QTc prolongation. No significant differences 
were noted, however, in terms of PFS (5.6 months in 
patients under 75 years vs. 5.5 months in ≥ 75 years) and 
OS (12.5 vs. 9.8 months) (38).
Recently, 3 randomized phase III trials demonstrated 
the superiority of combined BRAF and MEK inhibition 
over treatment with single-agent BRAF inhibitors, and 
BRAF plus MEK-targeted drugs are the new standard 
of care for BRAF-mutant advanced melanoma (39). 
Despite the lack of specifically designed trials, subgroup 
analyses of existing phase 3 trials suggest that the use of 
BRAF/MEK inhibitors seem to be as effective in elderly 
patients as in younger ones. In an exploratory analysis 
of clinical characteristics that may predict response to 
vemurafenib and cobimetinib (Co-BRIM trial), older age 
was not identified as a negative predictor for response: 
on the contrary, more complete responses were noted in 
patients aged > 65 years compared with younger patients 
(28% vs. 13%) (40).
In everyday clinical practice, current data suggest that 
BRAF/MEK inhibitors can be safely and effectively used 
in elderly patients and prescribing information recom-
mends no special dose adjustment for BRAF and MEK 
inhibitors in this subgroup of patients.
Impact of age on chemotherapy and radiotherapy
Therapeutic options for melanoma patients, both young 
and old, were limited until the most recent 5–7 years, 
during which period innovative drugs, including targeted 
agents and immune drugs, became available (41). Over 
recent years, older patients with metastatic melanoma, 
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who were previously not eligible for treatment because 
of concerns about toxicity and existing comorbidities, 
have been able to receive a variety of active immune 
and targeted therapies. Several chemotherapies have re-
ported limited activity in advanced melanoma, including 
dacarbazine, nitrosoureas, temozolomide, carboplatin 
and taxanes (42). The response rates to chemotherapy 
are similar in younger and older patients, both in terms 
of progression-free survival and OS. However, in old 
age, more deaths were observed due to comorbidity 
(43). The use of polychemotherapy in elderly patients is 
contra-indicated because of toxicity and comorbidities. 
Deterioration in renal and hepatic function, as well as 
cardiomyopathy, requires dose adjustment. Thus, organ 
toxicities must not be overlooked in elderly patients (44, 
45). Despite the different kinetic profiles of chemothera-
py, their efficacy is not age dependent. These concerns, 
however, are becoming uncommon, as chemotherapy has 
now been abandoned in most melanoma centres. 
Although melanoma was historically considered a 
radio-resistant tumour, radiation therapy remains a 
useful treatment option for patients with melanoma in 
some settings (46). It can provide effective palliation 
for patients who develop unresectable, locally recurrent, 
or symptomatic metastatic disease, such as bone pain, 
epidural spinal cord compression, or central nervous 
system symptoms. Radiotherapy, as well as chemo-
therapy, can impact on the bone marrow reservoir in 
older patients. Elderly subjects can develop myelos-
uppression, particularly if the patient is in a state of 
malnutrition. The use of colony-stimulating factors, 
such as G-CSF and recombinant erythropoietin, for the 
treatment of febrile neutropaenia and anaemia, respec-
tively, may be required more often in elderly patients. 
Moreover, age-related T-cell down-regulation and im-
munosenescence may explain the increased suscepti-
bility to infections with ageing. Therefore, despite 
similar efficacy of chemo therapy and radiotherapy in 
elderly patients, the evaluation of benefits with clinical 
outcome, adverse effects and impact on quality of life 
must be evaluated carefully.
CONCLUSION 
Age has an impact on melanoma risk factors as well as 
prognosis, SLN positivity and BRAF mutations. Age is 
also important when offering treatment options. Although 
immunotherapies and targeted therapies give similar 
responses in elderly patients, as well as comparable 
toxicity, albeit more non-melanoma skin cancers with 
targeted therapies, the impact of melanoma drugs in 
terms of frequent visits to hospital for regular infusions 
and imaging as well as toxicity needs to be assessed 
carefully, especially for elderly patients who have very 
little social support. 
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